1-3 of 3
Yong-xian Hu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Novel risk stratification of ph-like ALL cohort receiving CD19-directed CAR-T therapy

Free
Cai Zihong, Bailin He, Baiwei Luo, Zhixiang Wang, Wenhao Zhong, Xuan Zhou, Qifa Liu, Peng Li, Yong-xian Hu, Jing PAN, Liang Huang, Hongsheng Zhou
Journal: Blood
Blood (2025) 146 (Supplement 1): 5108.
https://doi.org/10.1182/blood-2025-5108
Published: 2025
Journal Articles

CTD402, allogeneic anti-CD7 CAR t-cell, in relapsed or refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) - report of clinical outcomes at the recommended phase 2 dose (RP2D)

Free
Peihua Lu, Yong-xian Hu, Xian Zhang, Junfang Yang, Xiaoyu Zhu, Ying Wang, Keshu Zhou, Sanbin Wang, Jiang Cao, Heng Mei, Kai Hu, Yong Yu, Yali Zhou, Eileen McNulty, Ming Gao, Maria Delrosario, Wengang Ge, Yajin Ni, Jiangtao Ren, Jan Davidson-Moncada, He Huang
Journal: Blood
Blood (2025) 146 (Supplement 1): 1042.
https://doi.org/10.1182/blood-2025-1042
Published: 2025
Journal Articles

CD7-targeted universal CAR T-cell therapy in relapsed or refractory (R/R) acute myeloid leukemia (AML): Clinical results from CTD401/402 studies

Free
Yong-xian Hu, Xiaoyu Zhu, Heng Mei, Ying Wang, Yali Zhou, Kangqi Bian, Maria del Rosario, Eileen McNulty, Ming Gao, Lu Han, Wengang Ge, Jan Davidson-Moncada, Jiangtao Ren, He Huang
Journal: Blood
Blood (2025) 146 (Supplement 1): 816.
https://doi.org/10.1182/blood-2025-816
Published: 2025